# To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.

> **NCT04848662** · PHASE1 · COMPLETED · sponsor: **Bond Avillion 2 Development LP** · enrollment: 12 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** BDA MDI (PT027) 160/180 μg
- **DRUG:** Pulmicort Respules 0.5 MG/ML Inhalation Suspension

## Key facts

- **NCT ID:** NCT04848662
- **Lead sponsor:** Bond Avillion 2 Development LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-06
- **Primary completion:** 2021-07-05
- **Final completion:** 2021-07-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04848662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04848662, "To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04848662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*